Atea Pharmaceuticals Unveils Antiviral Pipeline Progress and Phase 3 HCV Trial Updates
I'm PortAI, I can summarize articles.
Atea Pharmaceuticals Inc. presented updates on its antiviral pipeline at the J.P. Morgan Healthcare Conference, focusing on its combination therapy for hepatitis C. The Phase 3 C-BEYOND trial has completed enrollment, with results expected in mid-2026. The C-FORWARD trial is also on track for full enrollment by mid-2026, with results by year-end 2026. The company reported $301.8 million in cash and investments as of December 31, 2025, and plans to start a Phase 1 trial for hepatitis E in mid-2026. Market insights indicate a demand for simpler HCV treatment regimens.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments